<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368121</url>
  </required_header>
  <id_info>
    <org_study_id>EMMA-1</org_study_id>
    <nct_id>NCT00368121</nct_id>
  </id_info>
  <brief_title>EMMA-1 (Erbitux for Multiple Myeloma)</brief_title>
  <acronym>EMMA-1</acronym>
  <official_title>Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Andreas Engert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Clinical Trials Centre Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EMMA-1 is an open-label, non-randomized, two-stage phase II study. Patients with refractory&#xD;
      multiple myeloma stage II or III or relapsed disease after at least one line of treatment&#xD;
      will receive Cetuximab+/-Dexamethasone.&#xD;
&#xD;
      The planed treatment duration per patient is 16 weeks. Patients achieving a response or&#xD;
      stable disease after 16 weeks of treatment may continue study medication for 6 more months&#xD;
      (patients receiving Cetuximab alone) or for 3 more months (patients receiving Cetuximab plus&#xD;
      Dexamethasone). Responding patients who relapse during follow-up period of two years may&#xD;
      receive a second treatment with Cetuximab following initial study guidelines&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitable patients&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months)</measure>
    <time_frame>After 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of Cetuximab +/- Dexamethasone</measure>
    <time_frame>During 16 weeks of intervention and 8 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from treatment failure</measure>
    <time_frame>From the date of registration until the first event or (if none occurs) until the date of the last determination of continuing complete/partial remission.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from the date of registration until first documentation of progression/relapse of disease or death related to MM</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of registration until the date of death from any cause or (if the patients is alive) until the date of last information.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomic evaluation of response to treatment</measure>
    <time_frame>After 16 weeks of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cetuximab + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab +/- Dexamethasone</intervention_name>
    <description>Cetuximab dosing schedule:&#xD;
• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion&#xD;
Dexamethasone dosing schedule:&#xD;
• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.&#xD;
Mode of administration: orally</description>
    <arm_group_label>Cetuximab + Dexamethasone</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma diagnosed according to the Durie-criteria in stage II or III (Salmon&#xD;
             and Durie)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Refractory or relapsed disease after at least one line of treatment&#xD;
&#xD;
          -  Male or female &gt;= 18 years of age&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  ECOG performances status 0-2&#xD;
&#xD;
          -  If of childbearing potential, willingness to use effective contraceptive method for&#xD;
             the study duration and 6 months post-dosing.&#xD;
&#xD;
          -  No surgery, radiotherapy or chemotherapy or any investigational agent within 30 days&#xD;
             of study entry&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asecretory multiple myeloma&#xD;
&#xD;
          -  Patients eligible and willing to undergo high dose chemotherapy followed by autologous&#xD;
             stem cell transplantation&#xD;
&#xD;
          -  Prior allogeneic transplantation&#xD;
&#xD;
          -  Prior antibody or EGFR-pathway targeting therapy&#xD;
&#xD;
          -  Severe cardiovascular disease like functionally restricting heart rhythm disturbance&#xD;
             or heart malformation or severe hypertension, or cardiac insufficiency &gt; NYHA-II&#xD;
&#xD;
          -  HIV Infection, Hepatitis B or C&#xD;
&#xD;
          -  Brain disorders, psychiatric illness&#xD;
&#xD;
          -  Insufficient bone marrow reserve (Leucocytes &lt; 1500/µl; Thrombocytes &lt; 50000/µl)&#xD;
&#xD;
          -  Creatinine-Clearance &lt; 30 ml/min or Crea &gt; 3.0 mg/dl&#xD;
&#xD;
          -  Bilirubin &gt; 2 mg/dl; ASAT, ALAT &gt; 100 U/l&#xD;
&#xD;
          -  Pregnancy (absence confirmed by serum/urine beta-HCG) or breast-feeding&#xD;
&#xD;
          -  FEV1 &lt; 50% of the reference value&#xD;
&#xD;
          -  Active secondary malignancy&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Having participated in another clinical trial or any investigational agent in the&#xD;
             preceding 30 days&#xD;
&#xD;
          -  Known allergic/hypersensitivity reaction to any compounds of the treatment&#xD;
&#xD;
          -  Other previous malignancy within 5 years, with exception of a history of a previous&#xD;
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
&#xD;
          -  Known drug abuse/alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne, Department I of Internal Medicine</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital of Muenster, Internal Medicine A</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 23, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Andreas Engert</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

